Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prevacid TV Ad Revisions Increase Prominence Of Indication After FDA Letter

Executive Summary

TAP has revised its TV ad for Prevacid by increasing the prominence of the drug's indication in response to a letter from FDA's ad division

You may also be interested in...



DTC Is Not Improving, Rep. Waxman Says: Viagra Ads Show “Six” Sells?

The decline in advertising enforcement actions by FDA does not reflect better compliance in direct-to-consumer advertisements, House Government Reform Committee Ranking Member Henry Waxman (D-Calif.) maintains

DTC Is Not Improving, Rep. Waxman Says: Viagra Ads Show “Six” Sells?

The decline in advertising enforcement actions by FDA does not reflect better compliance in direct-to-consumer advertisements, House Government Reform Committee Ranking Member Henry Waxman (D-Calif.) maintains

TAP Prevacid

TAP is revising its 60-second "Heartbreak Hotel" ad in response to FDA objections. A March 15 letter from the ad division maintains that the ad did not sufficiently present the limitations to the indication for Prevacid or the side effect information. TAP has resolved the issue with the agency and a corrected version of the ad will run shortly, the Takeda/Abbott joint venture said

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel